CAMP4 Therapeutics Corporation

NasdaqGM CAMP

CAMP4 Therapeutics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending November 30, 2023: 35.78%

CAMP4 Therapeutics Corporation Gross Profit Margin is 35.78% for the Trailing 12 Months (TTM) ending November 30, 2023, a -6.79% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

CAMP4 Therapeutics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending November 30, 2022 was 38.38%, a -7.53% change year over year.
CAMP4 Therapeutics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending November 30, 2021 was 41.51%, a 8.06% change year over year.
CAMP4 Therapeutics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending November 30, 2020 was 38.41%, a -2.71% change year over year.
CAMP4 Therapeutics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending November 30, 2019 was 39.48%, a -3.35% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: CAMP

CAMP4 Therapeutics Corporation

CEO	Mr. Joshua Mandel-Brehm
IPO Date	Oct. 11, 2024
Location	United States
Headquarters	One Kendall Square Bldg 1400 West, 3rd Floor
Employees	58
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Key trends

Past 5 years